1
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, January 14, 2003: US06506762 (111 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 10, 2009: US07488740 (6 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


3
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng, Taeyoung Yoon: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, December 4, 2007: US07304059 (3 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


4
Stéphane De Lombaert
Raymond F Horvath, Jennifer N Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, February 24, 2004: US06696445 (3 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY


5
Stéphane De Lombaert
Taeyoung Yoon, Ping Ge, Stéphane De Lombaert, Raymond F Horvath, Dario Doller, Kevin J Hodgetts, Lu Yan Zhang, Bernd Kaiser, Xuechun Zhang, Yasuchika Yamaguchi, Cunyu Zhang, Jim Darrow: 5-substituted-2-arylpyrazines. Neurogen Corporation, Peter F Corless, Dwight D Kim, Edwards Angell Palmer & Dodge, February 20, 2007: US07179807 (2 worldwide citation)

Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators or CRF receptors. Compounds of the invention are provided by the following formula: The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and ...


6
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen, Pfizer, Sonia K Guterman, Lawson & Weitzen, July 11, 2006: US07074929

This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula II, IV, V, VII–IX and XI


7
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edward Angell Palmer & Dodge, November 19, 2009: US20090286767-A1

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


8

9
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stephane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Peter F Corless, John B Alexander, Edwards Angell Palmer & Dodge, July 11, 2006: US07074799 (23 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


10
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane DeLombaert, Kevin J Hodgetts, Xiaozhang Zheng: Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, October 7, 2008: US07432275 (8 worldwide citation)

Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated co ...